Replies to post #381874 on Innovation Pharmaceuticals Inc (IPIX)

[Rdunn88]

The problem with B is when? Too many unknowns to expect this stock to keep trading higher... The lock PR was the pump and dump play.....

[TradingPro]

It’s also not for moderate to severe patients. Which is lost in the shoot first ask questions later mentality. The problem with that mentality is B results are due next week so the smarter less emotional investors are replacing the traders which is good. But there is little time to get back in. If results are good Leo I’m sure will point out the treatments are for two different patient groups. Merck’s antiviral wasn’t bad, except maybe the potential side effects. The market seemed to know the difference then and IPIX didn’t get hit too hard. Next week are results for moderate to severe patients folks. Don’t be surprised with EUA , funding, partnership, etc. because we are competing against Rem, not mild Covid patient treatments.

[TheDane]

I wonder how they’re able to get these trials done so quickly. Are these Microwave vs. old fashioned oven trials? Granted the BrilAcidin trial actually ended three months ago and if we had a in house team doing the unblinding and analysis it would have been completed well over a month ago.

I haven’t read the whole report bu the targeted patient group seems much more specific than Brilacidn’s Moderate to severe.

Who knows. We’ll see what happens!

[thefamilyman]

It looks like the Pfizer drug is competition for Merck’s mutagenic drug. Both of which are for use early in the disease.

LilKahuna said,

The selling was nothing more than market reaction to the Pfizer news. The problem is, the drug is expensive. It’s fine for wealthier countries, but the rest of the world, the other 6 billion people, need a cheaper, effective treatment. Brilacidin is still in the running in dozens of markets.